{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:14:43Z","timestamp":1767136483940,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013720.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000}}],"reference-count":136,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013720.pub3","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T21:18:37Z","timestamp":1638307117000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline"],"prefix":"10.1002","volume":"2021","author":[{"given":"Luis","family":"Garegnani","sequence":"additional","affiliation":[{"name":"Associate Cochrane Centre; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hyland","sequence":"additional","affiliation":[{"name":"Paediatric Neurology Division \u2013 Paediatrics Department; Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Roson Rodriguez","sequence":"additional","affiliation":[{"name":"Research Department; Instituto Universitario Hospital Italiano; Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Central Library; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Associate Cochrane Centre; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"S1","key":"10.1002\/14651858.CD013720.pub3-BIB0001|cit1","first-page":"FV03","article-title":"Idebenone reduces loss of respiratory function in Duchenne muscular dystrophy: outcome of a phase III double blind, randomized, placebo-controlled trial","volume":"46","author":"Buyse","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0002|cit2","first-page":"S107","article-title":"Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy","volume":"3","author":"Buyse","year":"2016","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Buyse G Voit T Schara U Verschuuren J D'Angelo M Bernert G Idebenone reduces loss of respiratory function in Duchenne muscular dystrophy - outcome of a phase III double blind, randomised, placebo-controlled trial (DELOS) American Academy of Neurology 2015 84 Abstract: 15 1-442-AAN","DOI":"10.1212\/WNL.84.14_supplement.PL2.003"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3233\/JND-180338","article-title":"Home-based monitoring of pulmonary function in patients with Duchenne muscular dystrophy","volume":"5","author":"Buyse","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ppul.23547","article-title":"Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy","volume":"52","author":"Buyse","year":"2017","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.ejpn.2017.04.1206","article-title":"Idebenone preserves respiratory function above clinically relevant thresholds of FVC in Duchenne muscular dystrophy (DMD)","volume":"21","author":"Cirrincione","year":"2017","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0008|cit8","unstructured":"A phase III double-blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in 10 \u2013 18 year old patients with Duchenne muscular dystrophy - DELOS www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-012037-30\/FR"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0009|cit9","first-page":"S185","article-title":"Evaluating the effects of baseline variables on the respiratory function benefit of idebenone in Duchenne muscular dystrophy","volume":"5","author":"Hasham","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013720.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"P5.436","DOI":"10.1212\/WNL.90.15_supplement.P5.436","article-title":"Impact of idebenone on rate of respiratory function decline in Duchenne muscular dystrophy (DMD)","volume":"90","author":"Karafilidis","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0011|cit11","first-page":"A5865","article-title":"Effect of idebenone on respiratory function across various subgroups in patients with Duchenne muscular dystrophy (DMD)","volume":"197","author":"Karafilidis","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0012|cit12","first-page":"A5865","article-title":"Effect of idebenone on respiratory function across various subgroups in patients with Duchenne muscular dystrophy (DMD)","volume":"197","author":"Karafilidis","year":"2018","journal-title":"American Thoracic Society International Conference Abstracts"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0960-8966(18)30338-9","article-title":"Effect of idebenone on bronchopulmonary adverse events and hospitalizations in patients with Duchene muscular dystrophy (DMD)","volume":"28","author":"Lawrence","year":"2018","journal-title":"Neuromuscular Disorders"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013720.pub3-BIB0014|cit14","first-page":"OA2928","article-title":"Efficacy of idebenone in respiratory decline in Duchenne muscular dystrophy (DMD): comparison of analysis methods","volume":"50","author":"Leinonen","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"S4","key":"10.1002\/14651858.CD013720.pub3-BIB0015|cit15","first-page":"15","article-title":"Efficacy of idebenone in respiratory decline in Duchenne muscular dystrophy (DMD): comparison of analysis methods","volume":"59","author":"Leinonen","year":"2017","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"PS18_07","DOI":"10.1055\/s-0032-1307143","article-title":"DELOS phase III study with idebenone (Catena\u00ae) in Duchenne muscular dystrophy","volume":"43","author":"Lutz","year":"2012","journal-title":"Neuropediatrics"},{"issue":"3","key":"10.1002\/14651858.CD013720.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JND-170245","article-title":"Efficacy of idebenone to preserve respiratory function above clinically meaningful thresholds for forced vital capacity (FVC) in patients with Duchenne muscular dystrophy","volume":"4","author":"Mayer","year":"2017","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0018|cit18","first-page":"A6876","article-title":"Effect of idebenone on bronchopulmonary adverse events and hospitalizations in patients with Duchene muscular dystrophy (DMD)","volume":"195","author":"Mayer","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0019|cit19","unstructured":"Mayer O McDonald C Meier T Leinonen M Buyse G Effect of idebenone on bronchopulmonary adverse events and hospitalizations in patients with Duchene muscular dystrophy (DMD) American Journal of Respiratory and Critical Care Medicine 2017 195 A6876"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0020|cit20","first-page":"48","article-title":"Impact of idebenone on respiratory burden, including risk of bronchopulmonary complications, in Duchenne muscular dystrophy","volume":"5","author":"Mayer","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0021|cit21","first-page":"S321","article-title":"Alternative analyses of respiratory function in Duchenne muscular dystrophy: consistent treatment benefit of idebenone","volume":"5","author":"Mayer","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0022|cit22","first-page":"S107","article-title":"Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy","volume":"3","author":"McDonald","year":"2016","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013720.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nmd.2016.05.008","article-title":"Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy","volume":"26","author":"McDonald","year":"2016","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0024|cit24","unstructured":"Phase III study of idebenone in Duchenne muscular dystrophy (DMD) clinicaltrials.gov\/ct2\/show\/NCT01027884"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013720.pub3-BIB0025|cit25","first-page":"OA2927","article-title":"Effects of idebenone on pulmonary morbidity in Duchenne muscular dystrophy (DMD)","volume":"50","author":"Rummey","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"S4","key":"10.1002\/14651858.CD013720.pub3-BIB0026|cit26","first-page":"29","article-title":"Effect of idebenone on bronchopulmonary adverse events and hospitalizations in patients with Duchene muscular dystrophy (DMD)","volume":"59","author":"McDonald","year":"2017","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0960-8966(18)30339-0","article-title":"Efficacy of idebenone in respiratory decline in Duchenne muscular dystrophy (DMD): comparison of analysis methods","volume":"28","author":"Warnock","year":"2018","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Warnock A Lawrence C Leinonen M Buyse G Efficacy of idebenone in respiratory decline in Duchenne muscular dystrophy (DMD): comparison of analysis methods Neuromuscular Disorders 2018 28 Suppl 1 S17","DOI":"10.1016\/S0960-8966(18)30339-0"},{"issue":"S1","key":"10.1002\/14651858.CD013720.pub3-BIB0029|cit29","first-page":"S103","article-title":"A phase III double-blind, randomized, placebo controlled study (SIDEROS) assessing the efficacy of idebenone in slowing the rate of respiratory function loss in patients with Duchenne muscular dystrophy receiving glucocorticoid steroids","volume":"3","author":"Buyse","year":"2016","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0030|cit30","unstructured":"A clinical study to assess how effective and safe is idebenone treatment in patients with Duchenne muscular dystrophy (DMD) who are currently receiving glucocorticoid steroids www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-000602-10\/AT"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0031|cit31","unstructured":"A Phase III double-blind study with idebenone in patients with Duchenne muscular dystrophy (DMD) taking glucocorticoid steroids clinicaltrials.gov\/ct2\/show\/NCT02814019"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0032|cit32","unstructured":"Santhera Pharmaceuticals Holding AG Santhera to discontinue phase 3 SIDEROS study and development of Puldysa\u00ae in Duchenne muscular dystrophy (DMD) and focus on vamorolone www.santhera.com\/assets\/files\/press-releases\/2020-10-06_SiderosPuldysa_e_final.pdf"},{"issue":"5","key":"10.1002\/14651858.CD013720.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-0404.1988.tb03681.x","article-title":"Selenium and vitamin E treatment of Duchenne muscular dystrophy: no effect on muscle function","volume":"78","author":"B\u00e4ckman","year":"1988","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0034|cit34","first-page":"49","article-title":"Pilot study of flavocoxid in ambulant DMD patients","volume":"33","author":"Barcellona","year":"2014","journal-title":"Acta Myologica"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1212\/WNL.35.1.61","article-title":"Chronic allopurinol and adenine therapy in Duchenne muscular dystrophy: effects on muscle function, nucleotide degradation, and muscle ATP and ADP content","volume":"35","author":"Palmieri","year":"1985","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0036|cit36","first-page":"S138","article-title":"Successful pilot trial of L-arginine and metformin in Duchenne's muscular dystrophy","volume":"1","author":"Bonati","year":"2014","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"PS02","DOI":"10.1055\/s-0035-1550745","article-title":"Improved muscle function in Duchenne muscular dystrophy using a combination of l-arginine and metformin","volume":"46","author":"Bonati","year":"2015","journal-title":"Neuropediatrics"},{"issue":"10","key":"10.1002\/14651858.CD013720.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"e1914171","DOI":"10.1001\/jamanetworkopen.2019.14171","article-title":"Effect of combination l-citrulline and metformin treatment on motor function in patients with Duchenne muscular dystrophy: a randomized clinical trial","volume":"2","author":"Hafner","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0039|cit39","first-page":"S116","article-title":"L-citrulline and metformin delay muscle degeneration in Duchenne muscular dystrophy: results from a randomised clinical trial","volume":"5","author":"Hafner","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"S1","key":"10.1002\/14651858.CD013720.pub3-BIB0040|cit40","first-page":"S30","article-title":"Succesful pilot trial of L-arginine and metformin in Duchenne's muscular dystrophy","volume":"125","author":"Hafner","year":"2014","journal-title":"Clinical Neurophysiology"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13063-016-1503-1","article-title":"Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial","volume":"17","author":"Hafner","year":"2016","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0042|cit42","unstructured":"L-citrulline and metformin in Duchenne's muscular dystrophy clinicaltrials.gov\/ct2\/show\/NCT01995032"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD013720.pub3-BIB0043|cit43","first-page":"A79","article-title":"Double-blind randomized controlled trial of SNT-MC17\/idebenone in Duchenne muscular dystrophy","volume":"70","author":"Buyse","year":"2008","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013720.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ppul.22688","article-title":"Effects of glucocorticoids and idebenone on respiratory function in patients with Duchenne muscular dystrophy","volume":"48","author":"Buyse","year":"2013","journal-title":"Pediatrics Pulmonology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/j.nmd.2015.06.277","article-title":"Idebenone improves respiratory function in pediatric and adolescent patients with Duchenne muscular dystrophy not using glucocorticoid steroids","volume":"25","author":"Buyse","year":"2015","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1090-3798(15)30041-6","article-title":"Idebenone as a new therapy to treat respiratory function loss in Duchenne muscular dystrophy: from preclinical studies to phase III trial outcome","volume":"19","author":"Buyse","year":"2015","journal-title":"European Journal of Paediatric Neurology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.nmd.2019.06.375","article-title":"Consistent long-term effect of idebenone in reducing respiratory function decline in advanced patients with Duchenne muscular dystrophy","volume":"29","author":"Buyse","year":"2019","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD013720.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.nmd.2011.02.016","article-title":"Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial","volume":"21","author":"Buyse","year":"2011","journal-title":"Neuromuscular Disorders"},{"issue":"12","key":"10.1002\/14651858.CD013720.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/WNL.0b013e31824c46be","article-title":"Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial","volume":"78","author":"Escolar","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0050|cit50","unstructured":"A Phase IIa double blind, randomised, placebo controlled, single centre study at the University of Leuven to assess the efficacy and tolerability of idebenone in 10 - 16 year old males with cardiac dysfunction associated with Duchenne muscular dystrophy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-002520-33\/BE"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0051|cit51","unstructured":"A study to investigate the safety, tolerability, and efficacy of SGT-001 in male adolescents and children with Duchenne muscular dystrophy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002213-60\/GB"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0052|cit52","unstructured":"A phase III open-label extension study to assess the long-term safety and efficacy of idebenone in patients with Duchenne muscular dystrophy (DMD) who completed the SIDEROS study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004279-30\/GB"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0053|cit53","unstructured":"A 3-part, randomized, double blind, adaptive seamless phase 1-3 study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 in non-ambulatory patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy and evidence of respiratory deterioration clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004602-94\/BE"},{"issue":"11","key":"10.1002\/14651858.CD013720.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/mus.880111110","article-title":"Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E","volume":"11","author":"Fenichel","year":"1988","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1002\/14651858.CD013720.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archneur.1983.04050050062009","article-title":"Effects of allopurinol in Duchenne's muscular dystrophy","volume":"40","author":"Hunter","year":"1983","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.880020108","article-title":"Lack of benefit of allopurinol in Duchenne dystrophy","volume":"2","author":"Mendell","year":"1979","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0058|cit58","unstructured":"CoQ10 and prednisone in non-ambulatory DMD clinicaltrials.gov\/ct2\/show\/NCT00308113"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0059|cit59","unstructured":"A phase III open-label extension study to assess the long-term safety and efficacy of idebenone in patients with Duchenne muscular dystrophy (DMD) who completed the SIDEROS study clinicaltrials.gov\/ct2\/show\/NCT03603288"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/WNL.31.4.422","article-title":"The progression of Duchenne muscular dystrophy: clinical trial of allopurinol therapy","volume":"31","author":"Stern","year":"1981","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013720.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archneur.1982.00510180020004","article-title":"Drug trial of superoxide dismutase in Duchenne's muscular dystrophy","volume":"39","author":"Stern","year":"1982","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0062|cit62","first-page":"OA5330","article-title":"Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD)","volume":"54","author":"Mayer","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0063|cit63","first-page":"OA5331","article-title":"Long term efficacy: idebenone reduces the rate of both inspiratory and expiratory functional loss in Duchenne muscular dystrophy (DMD)","volume":"54","author":"Mayer","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0064|cit64","first-page":"A7449","article-title":"Treatment effect of idebenone on inspiratory flow reserve (IFR) in patients with Duchenne muscular dystrophy (DMD): long term analysis from the SYROS study","volume":"199","author":"Mayer","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.nmd.2019.06.378","article-title":"P.264SYROS study \u2013 long-term reduction in rate of respiratory function decline in patients with Duchenne muscular dystrophy treated with idebenone","volume":"29","author":"Servais","year":"2019","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2019.10.008.","article-title":"Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy","volume":"30","author":"Servais","year":"2020","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0387-7604(82)80007-7","article-title":"Xanthine oxidase inhibitor in Duchenne muscular dystrophy","volume":"4","author":"Tamari","year":"1982","journal-title":"Brain & Development"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0068|cit68","unstructured":"SUNIMUD - sunphenon EGCg (epigallocatechin-gallate) in Duchenne muscular dystrophy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-016482-28\/DE"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0069|cit69","unstructured":"Sunphenon epigallocatechin-gallate (EGCg) in Duchenne muscular dystrophy clinicaltrials.gov\/ct2\/show\/NCT01183767"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0070|cit70","first-page":"550","article-title":"Focused conference group: P10 - drugs for half the world: paediatric clinical pharmacology clinical trial of epigallocatechin-3-gallate in Duchenne muscular dystrophy","volume":"107 (Suppl 1)","author":"Ruegg","year":"2010","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"8-9","key":"10.1002\/14651858.CD013720.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"P612","DOI":"10.1016\/j.nmd.2009.06.215","article-title":"T.P.3.08 Clinical trial of epigallocatechin-3-gallate in Duchenne muscular dystrophy","volume":"19","author":"Von Moers","year":"2009","journal-title":"Neuromuscular Disorders"},{"issue":"12","key":"10.1002\/14651858.CD013720.pub3-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001941.pub3","article-title":"Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders","author":"Annane","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3390\/biomedicines6010001","article-title":"Skipping multiple exons to treat DMD-promises and challenges","volume":"6","author":"Tejal","year":"2018","journal-title":"Biomedicines"},{"issue":"3","key":"10.1002\/14651858.CD013720.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nm.1916","article-title":"Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle","volume":"15","author":"Bellinger","year":"2009","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013720.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure for neuromuscular diseases. Construction and validation study","volume":"15","author":"B\u00e9rard","year":"2005","journal-title":"Neuromuscular Disorders: NMD"},{"issue":"3","key":"10.1002\/14651858.CD013720.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1002\/14651858.CD013720.pub3-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009068.pub3","article-title":"Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy","author":"Bourke","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"C817","DOI":"10.1152\/ajpcell.00139.2004","article-title":"Calcium, ATP, and ROS: a mitochondrial love-hate triangle","volume":"287","author":"Brookes","year":"2004","journal-title":"American Journal of Physiology. Cell Physiology"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1152\/japplphysiol.90985.2008","article-title":"Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests","volume":"106","author":"Burdi","year":"2009","journal-title":"Journal of Applied Physiology"},{"issue":"9979","key":"10.1002\/14651858.CD013720.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"issue":"1-2","key":"10.1002\/14651858.CD013720.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0891-5849(98)00205-6","article-title":"Mitochondrial function is differentially affected upon oxidative stress","volume":"26","author":"Cardoso","year":"1999","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0083|cit83","unstructured":"Covidence Veritas Health Innovation"},{"issue":"12","key":"10.1002\/14651858.CD013720.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Du Bois","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0085|cit85","unstructured":"Raxone www.ema.europa.eu\/en\/documents\/overview\/raxone-epar-summary-public_en.pdf"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1164\/rccm.200307-885ST","article-title":"Respiratory care of the patient with duchenne muscular dystrophy: ATS consensus statement","volume":"170","author":"Finder","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S239\u201341","DOI":"10.1542\/peds.2008-2952I","article-title":"A 2009 perspective on the 2004 American Thoracic Society statement, \"Respiratory Care of the Patient With Duchenne Muscular Dystrophy\"","volume":"123","author":"Finder","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ppul.24605","article-title":"Therapies that are available and under development for Duchenne muscular dystrophy: what about lung function?","volume":"55","author":"Pavlou","year":"2020","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0089|cit89","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"8","key":"10.1002\/14651858.CD013720.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00001756-199612200-00070","article-title":"Oxidative damage to muscle protein in Duchenne muscular dystrophy","volume":"8","author":"Haycock","year":"1996","journal-title":"Neuroreport"},{"issue":"23","key":"10.1002\/14651858.CD013720.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1113\/JP275232","article-title":"Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat","volume":"595","author":"Head","year":"2017","journal-title":"Journal of Physiology"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","article-title":"The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/1440-1681.12521","article-title":"Beneficial cilostazol therapeutic effects in mdx dystrophic skeletal muscle","volume":"43","author":"Hermes Tde","year":"2016","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-079X.2011.00871.x","article-title":"Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy","volume":"51","author":"Hibaoui","year":"2011","journal-title":"Journal of Pineal Research"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0096|cit96","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 6.2\u00a0(updated February\u00a02021).\u00a0Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0097|cit97","unstructured":"Higgins JPT \u00a0Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).\u00a0Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD013720.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2337\/dc12-1708","article-title":"Identification of minimal clinically important difference scores of the PedsQL in children, adolescents, and young adults with type 1 and type 2 diabetes","volume":"36","author":"Hilliard","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2353\/ajpath.2007.060344","article-title":"Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice","volume":"170","author":"Hnia","year":"2007","journal-title":"American Journal of Pathology"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"20585","DOI":"10.1038\/s41598-020-77197-6","article-title":"Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study","volume":"10","author":"Kawamura","year":"2020","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JND-140053","article-title":"Compliance to care guidelines for Duchenne muscular dystrophy","volume":"2","author":"Landfeldt","year":"2015","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD013720.pub3-BIB0102|cit102","first-page":"1043","article-title":"Meta-analysis of two clinical trials: slowing respiratory decline in Duchenne muscular dystrophy (DMD)","volume":"50","author":"Leinonen","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD013720.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1701418","DOI":"10.1183\/13993003.01418-2017","article-title":"Evolution of respiratory function in Duchenne muscular dystrophy from childhood to adulthood","volume":"51","author":"LoMauro","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD013720.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1378\/chest.108.3.779","article-title":"Indicators of need for mechanical ventilation in Duchenne muscular dystrophy and spinal muscular atrophy","volume":"108","author":"Lyager","year":"1995","journal-title":"Chest"},{"issue":"8","key":"10.1002\/14651858.CD013720.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"e0182449","DOI":"10.1371\/journal.pone.0182449","article-title":"Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein","volume":"12","author":"M\u00e2ncio","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nut.2017.07.003","article-title":"Vitamin E treatment decreases muscle injury in mdx mice","volume":"43-4","author":"M\u00e2ncio","year":"2017","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1556\/ABiol.61.2010.2.5","article-title":"Myocardial fibrosis is unaltered by long-term administration of L-arginine in dystrophin deficient mdx mice: a histomorphometric analysis","volume":"61","author":"Marques","year":"2010","journal-title":"Acta Biologica Hungarica"},{"issue":"5","key":"10.1002\/14651858.CD013720.pub3-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"Matthews","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013720.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"C699","DOI":"10.1152\/ajpcell.00341.2014","article-title":"SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models","volume":"308","author":"M\u00e1zala","year":"2015","journal-title":"American Journal of Physiology. Cell Physiology"},{"issue":"3","key":"10.1002\/14651858.CD013720.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.23810","article-title":"Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy","volume":"48","author":"Mendell","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00418-008-0390-2","article-title":"Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological study","volume":"129","author":"Nakae","year":"2008","journal-title":"Histochemistry and Cell Biology"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0115|cit115","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002829.pub2","article-title":"Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease","author":"Orrell","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.2010.05634.x","article-title":"Oxidative stress caused by mitochondrial calcium overload","volume":"1201","author":"Peng","year":"2010","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD013720.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.4054","article-title":"Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy","volume":"228","author":"Percival","year":"2012","journal-title":"Journal of Pathology"},{"issue":"8","key":"10.1002\/14651858.CD013720.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013720.pub3-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004571.pub2","article-title":"Calcium antagonists for Duchenne muscular dystrophy","author":"Phillips","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0120|cit120","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"9","key":"10.1002\/14651858.CD013720.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0891-5849(03)00141-2","article-title":"Patients with dystrophinopathy show evidence of increased oxidative stress","volume":"34","author":"Rodriguez","year":"2003","journal-title":"Free Radical Biology & Medicine"},{"issue":"25","key":"10.1002\/14651858.CD013720.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"13818","DOI":"10.1073\/pnas.250379497","article-title":"Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy","volume":"97","author":"Sander","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0123|cit123","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence.\u00a0In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).\u00a0Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from\u00a0training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0124|cit124","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions.\u00a0In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).\u00a0Cochrane Handbook for Systematic Reviews of Interventions\u00a0Version 6.2\u00a0(updated February\u00a02021).\u00a0Cochrane, 2021 Available from\u00a0training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013720.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nmd.2012.10.022","article-title":"Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients","volume":"23","author":"Servais","year":"2013","journal-title":"Neuromuscular Disorders: NMD"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0126|cit126","unstructured":"Shawi F Perras C Severn M Emerging Drugs for Duchenne Muscular Dystrophy CADTH Issues in Emerging Health Technologies 2017 161"},{"key":"10.1002\/14651858.CD013720.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"9-10","key":"10.1002\/14651858.CD013720.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.nmd.2012.06.256","article-title":"S.P.31 What was the age and cause of death in patients with Duchenne muscular dystrophy in Sweden during 2000\u20132010?","volume":"22","author":"Stromberg","year":"2012","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD013720.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.nut.2011.09.013","article-title":"Ascorbic acid protects the diaphragm muscle against myonecrosis in mdx mice","volume":"28","author":"Tonon","year":"2012","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"},{"issue":"6192","key":"10.1002\/14651858.CD013720.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/335735a0","article-title":"Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice","volume":"335","author":"Turner","year":"1988","journal-title":"Nature"},{"issue":"8","key":"10.1002\/14651858.CD013720.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL\u2122 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory\u2122 Version 4.0 Generic Core Scales in Healthy and Patient Populations","volume":"39","author":"Varni","year":"2001","journal-title":"Medical Care"},{"issue":"6","key":"10.1002\/14651858.CD013720.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","article-title":"Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D","volume":"14","author":"Walters","year":"2005","journal-title":"Quality of Life Research"},{"issue":"8","key":"10.1002\/14651858.CD013720.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1590\/0004-282x20190088","article-title":"Duchenne muscular dystrophy: an historical treatment review","volume":"77","author":"Werneck","year":"2019","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"6","key":"10.1002\/14651858.CD013720.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","article-title":"Development of the EQ-5D-Y: a child-friendly version of the EQ-5D","volume":"19","author":"Wille","year":"2010","journal-title":"Quality of Life Research"},{"issue":"11","key":"10.1002\/14651858.CD013720.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"E713","DOI":"10.3390\/nu8110713","article-title":"Nutraceuticals and their potential to treat Duchenne muscular dystrophy: separating the credible from the conjecture","volume":"8","author":"Woodman","year":"2016","journal-title":"Nutrients"},{"issue":"9","key":"10.1002\/14651858.CD013720.pub3-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013720","article-title":"Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline","author":"Hyland","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T15:30:58Z","timestamp":1761233458000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013720.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":136,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013720.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}